JP2020523342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523342A5 JP2020523342A5 JP2019568236A JP2019568236A JP2020523342A5 JP 2020523342 A5 JP2020523342 A5 JP 2020523342A5 JP 2019568236 A JP2019568236 A JP 2019568236A JP 2019568236 A JP2019568236 A JP 2019568236A JP 2020523342 A5 JP2020523342 A5 JP 2020523342A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- composition
- mass
- baicalein
- oroxylin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520141P | 2017-06-15 | 2017-06-15 | |
| US62/520,141 | 2017-06-15 | ||
| PCT/US2018/037454 WO2018232063A1 (en) | 2017-06-15 | 2018-06-14 | Compositions and methods for beta secretase inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523342A JP2020523342A (ja) | 2020-08-06 |
| JP2020523342A5 true JP2020523342A5 (cg-RX-API-DMAC10.html) | 2021-07-26 |
| JP7209645B2 JP7209645B2 (ja) | 2023-01-20 |
Family
ID=64655980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568236A Active JP7209645B2 (ja) | 2017-06-15 | 2018-06-14 | βセクレターゼの阻害のための組成物および方法 |
| JP2019569247A Active JP6796217B2 (ja) | 2017-06-15 | 2018-06-15 | 神経保護組成物とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569247A Active JP6796217B2 (ja) | 2017-06-15 | 2018-06-15 | 神経保護組成物とその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11458117B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3638277B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7209645B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20190134809A (cg-RX-API-DMAC10.html) |
| CA (2) | CA3063751C (cg-RX-API-DMAC10.html) |
| ES (1) | ES3005508T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI3638277T3 (cg-RX-API-DMAC10.html) |
| PL (2) | PL3638277T3 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2018232063A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3638277T3 (pl) * | 2017-06-15 | 2025-03-10 | Sami Labs Limited | Kompozycje i sposoby hamowania beta sekretazy |
| US12465585B2 (en) * | 2018-06-15 | 2025-11-11 | Sami-Sabinsa Group Limited | Compositions for the management of seizure induced neurotoxicity |
| CN110115712A (zh) * | 2019-07-04 | 2019-08-13 | 兰州大学 | 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用 |
| EP4021397A4 (en) * | 2019-08-26 | 2023-09-27 | Sami-Sabinsa Group Limited | HERBAL ACTIVE INGREDIENTS AND THEIR EFFECT AGAINST POLLUTION |
| CN114246879B (zh) * | 2021-12-30 | 2023-10-27 | 沈阳兴齐眼药股份有限公司 | 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945518B2 (en) * | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
| CA2703698C (en) * | 2002-04-30 | 2016-11-22 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| US8034387B2 (en) * | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| NZ545565A (en) * | 2003-09-02 | 2009-06-26 | Unigen Pharmaceuticals Inc | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| KR20080091436A (ko) * | 2006-01-09 | 2008-10-13 | 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 | 위장관 독성, 관련 증상 및 궤양 치료용 천연물질 |
| EP1986670B1 (en) * | 2006-02-21 | 2017-06-28 | Council of Scientific and Industrial Research | Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof |
| US20100029654A1 (en) * | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| KR20080008929A (ko) * | 2006-11-20 | 2008-01-24 | 대한민국(관리부서 식품의약품 안전청장) | 오록실린 ａ를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품 |
| EP2890391A4 (en) * | 2012-08-29 | 2016-03-09 | Mannkind Corp | METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA |
| CA3043168C (en) * | 2016-11-11 | 2021-05-18 | Sami Labs Limited | Composition containing oroxylin a and method of extraction thereof |
| PL3638277T3 (pl) * | 2017-06-15 | 2025-03-10 | Sami Labs Limited | Kompozycje i sposoby hamowania beta sekretazy |
-
2018
- 2018-06-14 PL PL18816475.0T patent/PL3638277T3/pl unknown
- 2018-06-14 KR KR1020197034396A patent/KR20190134809A/ko not_active Ceased
- 2018-06-14 FI FIEP18816475.0T patent/FI3638277T3/fi active
- 2018-06-14 JP JP2019568236A patent/JP7209645B2/ja active Active
- 2018-06-14 CA CA3063751A patent/CA3063751C/en active Active
- 2018-06-14 WO PCT/US2018/037454 patent/WO2018232063A1/en not_active Ceased
- 2018-06-14 ES ES18816475T patent/ES3005508T3/es active Active
- 2018-06-14 EP EP18816475.0A patent/EP3638277B1/en active Active
- 2018-06-14 US US16/008,219 patent/US11458117B2/en active Active
- 2018-06-15 CA CA3063757A patent/CA3063757C/en active Active
- 2018-06-15 WO PCT/US2018/037724 patent/WO2018232224A1/en not_active Ceased
- 2018-06-15 US US16/009,490 patent/US10894029B2/en active Active
- 2018-06-15 PL PL18817403.1T patent/PL3638278T3/pl unknown
- 2018-06-15 JP JP2019569247A patent/JP6796217B2/ja active Active
- 2018-06-15 KR KR1020197033007A patent/KR20190131589A/ko not_active Ceased
- 2018-06-15 EP EP18817403.1A patent/EP3638278B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240350453A1 (en) | Methods of treating neurological and psychiatric disorders | |
| P Cardinali et al. | Clinical aspects of melatonin intervention in Alzheimer's disease progression | |
| FI3638277T3 (fi) | Koostumukset ja menetelmät beetasekretaasin estämiseksi | |
| MX2008000250A (es) | Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y | |
| CN114870018A (zh) | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 | |
| CA2511619A1 (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| US20180200259A1 (en) | GALANTAMINE CLEARANCE OF AMYLOID ß | |
| JP4880223B2 (ja) | スクシネートエステル誘導体の痴呆症の治療への使用 | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| CA2716966A1 (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| CN103156876A (zh) | 一种治疗中枢神经系统疾病的药物组合物及其制备方法和用途 | |
| JP2020502106A (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| JP7295145B2 (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
| KR20210113240A (ko) | 신경 변성 질환의 예방 또는 치료약 | |
| KR20060128961A (ko) | 중추신경계 질환 또는 질병의 치료 및 관리를 위해탈리도미드를 사용하는 방법 및 조성물 | |
| KR20180129692A (ko) | 홍경천 및 연자육을 포함하는 수면 장애 개선용 조성물 | |
| JP2024507940A (ja) | 小児期発症てんかん症候群の治療におけるカンナビジオール及びクロバザムの使用 | |
| JP2023531750A5 (cg-RX-API-DMAC10.html) | ||
| DE69808607T2 (de) | Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz | |
| CN111617255B (zh) | 用于治疗中枢神经系统紊乱的组合疗法 | |
| JP7638004B2 (ja) | 認知症の治療 | |
| CN112569217B (zh) | 戊酸衍生物在治疗遗传性小脑共济失调中的应用 | |
| WO2025143100A1 (ja) | 神経変性疾患治療剤 | |
| JP2024542844A5 (cg-RX-API-DMAC10.html) | ||
| CN111671757A (zh) | 3-[4-（4-吗啉基）-7h-吡咯并[2,3-d]嘧啶-5-基]苯甲腈制药用途 |